Sepsis is characterized by whole-body inflammation to overwhelming infection (1) . Over the last thirty years, sepsis' incidence has risen, indicating a need for a better understanding of its complex pathophysiology (2, 3) . The growth factor granulocyte macrophage colony stimulating factor (GM-CSF) elicits multiple changes in cells expressing its cognate receptor. Yet, despite GM-CSF's multiple functions and known relationship with innate leukocytes, its in vivo cellular source and role in sepsis remain uncertain (4) .
Profiling of GM-CSF expression by flow cytometry led to a surprising observation. Among the organs, the bone marrow and spleen contained the majority of GM-CSF + cells in the steady state (1.0 ± 0.1  10 6 and 2.9 ± 0.8  10 5 cells, respectively) ( Fig. 1A) (5) . In response to lipopolysaccharide (LPS), a component of gram negative bacteria, GM-CSF + cells increased in number preferentially in the spleen (3.2 ± 0.2  10 6 cells), and were predominantly B220 + MHCII + CD19 + IgM + B cells ( Fig. 1B and fig. S1, A and B ). This is surprising because GM-CSF is believed to be produced in vivo by non-hematopoietic cells, macrophages, and, in some cases, T cells (4, 6) . Nevertheless, B cells constituted the largest GM-CSF + population under these conditions (fig. S1C), a finding that we confirmed by Western blot analysis (Fig. 1C ). We named these B cells innate response activator (8) . We therefore elected to characterize murine IRA-B cells in more detail.
Immunofluorescence of spleen sections from LPS recipients co-localized the GM-CSF signal with round mononuclear cells expressing IgM, B220, PAX5, and CD19 ( Fig. 1D and fig. S1D ) in the red pulp ( Fig. 1 , E and F). RT-PCR experiments conducted on sorted cells and unprocessed tissue from wild type or B cell-deficient μMT mice indicated that B cells produce GM-CSF ( Fig. 1G ). Serum GM-CSF levels were negligible (i.e., below the 7.8 pg/ml detection limit of the assay), a finding that is consistent with the observation that GM-CSF is rapidly removed through receptor-mediated clearance (9) . Collectively, these data indicate that inflammation expands the IRA-B cell population in vivo.
B cells are linked developmentally, reside in different regions, and mediate distinct functions (10) (11) (12) (13) (14) . We profiled / www.sciencexpress.org / 12 January 2012 / Page 2 / 10.1126/science.1215173 IRA-B cells according to several well-established methods (13, 15, 16) . Our experiments revealed that (CD19 + B220 + MHCII + GM-CSF + ) IRA-B cells are phenotypically unique. They are: IgM high CD23 low CD43 high CD93 + (Fig. 2, A S7 ). These findings confirm that B1a B cells travel to the spleen in response to peritoneal TLR stimuli (18, 19) , and indicate that, upon splenic accumulation, B1a B cells can differentiate to IRA-B cells.
The ontogenic relationship between B1a and IRA-B cells raised the question whether IRA-B cells constitute a distinct subset. To elucidate this, we first placed peritoneal B1a B cells in culture. In response to LPS, B1a B cells separated into three discrete populations: CD138cells resembling "unchanged" B1a B cells, and two populations of CD138 + cells, IRA-B cells among them ( fig. S8A ). In vitro, IRA-B cells spontaneously secreted GM-CSF ( fig. S8B ). Second, we sorted peritoneal B1a B cells, IRA-B cells, and splenic CD43 + CD138 + cells, and followed their fate in vivo. B1a B cells gave rise to multiple cell types ( fig. S9A ), including IRA-B and CD43 + CD138 + cells, whereas (CD43 high CD138 + ) IRA-B and CD43 + CD138 + cells remained phenotypically segregated ( fig. S9, B and C). The data suggest that B1a B cells give rise to distinct cells. IRA-B cells are a subset of this group.
Surface phenotype and fate-mapping studies, though important, reveal little about function. How IRA-B cells arise was our next question. Expectedly, B cell-deficient μMT (20) and Cd19 -/-(21) mice did not develop IRA-B cells (Fig. 3 , C and D). Surprisingly, Tnfrsf13c -/mice lacking the B-cell activating factor receptor (BAFFR) failed to generate IRA-B cells; BAFFR is believed to be dispensable to B1 B cells (22) . At the level of microbial recognition, mice lacking the LPS receptor TLR4 or its adaptor MyD88, but not TRIF, did not generate IRA-B cells (Fig. 3 , C and D), indicating a specific MyD88-dependent pathway. The process could depend on direct B1a binding to LPS via TLR4, or on indirect, extrinsic factors such as TLR4-expressing macrophages. To discriminate between these two possibilities, we adoptively transferred B1a B cells from wt mice into Tlr4 -/mice ( Fig.  3E ). B1a wt B cells, but not endogenous Tlr4 -/-B cells, differentiated to IRA-B cells, indicating that direct TLR4 signaling on B1a B cells is sufficient to generate IRA-B cells.
To test whether IRA-B cells are restricted to TLR4mediated recognition, we injected TLR ligands Pam3CSK4 (ligand for TLR1/2), Poly(I:C) (TLR3), FLA-ST (TLR5), FSL-1 (TLR2/6), R848 (TLR7/8), and CpG ODN1668 (TLR9). The ligands Pam3CSK4, FSL-1 and R848 yielded IRA-B cells ( fig. S10A ), a finding that we confirmed in vitro ( fig. S10B ). We also wondered whether GM-CSF can play an autocrine role for B1a-IRA-B cell conversion (23) . B1a cells expressed Csf2Rβ (CD131) ( fig. S11A ) and, when placed in culture with antibodies against CD131, failed to give rise to IRA-B cells ( fig. S11 , B and C), but remained alive and gave rise to CD43 + CD138 + cells. Thus, IRA-B cells develop via MyD88-dependent pathways and use GM-CSF as an autocrine factor.
The spleen's open circulation (24) allows blood leukocytes to enter and exit easily. To reside in the spleen, leukocytes resort to adhesive ligands; MZ B cells, for example, rely on VLA-4 and LFA-1 (25) . We wondered whether splenic IRA-B cells, which express VLA-4 and LFA-1 at high levels, might behave similarly. Injection of neutralizing antibodies to VLA-4 and LFA-1 diminished IRA-B cell numbers, revealing that, indeed, the two integrins are responsible for retention ( Fig. 3F) .
Are IRA-B cells functionally important? To answer this, we focused on the cecal ligation and puncture (CLP) sepsis model (26) . We generated mixed chimeras by reconstituting lethally irradiated mice with μMT and GM-CSF-deficient on January 12, 2012 www.sciencemag.org Downloaded from / www.sciencexpress.org / 12 January 2012 / Page 3 / 10.1126/science.1215173 (Csf2 -/-) bone marrow cells. In these mice (called GM/μMT chimeras), the μMT marrow contributed all leukocytes except B cells whereas the Csf2 -/marrow contributed only Csf2 -/cells. Consequently, the only population completely lacking the capacity to produce GM-CSF in the reconstituted mice were B cells. We tested the quality of the chimeras and their controls by PCR ( fig. S11, A and B ) and by flow cytometry (fig. S11, C and D) .
In response to severe CLP, 40% of control mice survived and recovered, but every GM/μMT chimera died within 2 days (Fig. 4, A and B ). To characterize this phenotype further, we profiled GM/μMT chimeras and controls for several sepsis-relevant indices 20 hours after CLP, prior to any mortalities. Compared to IRA-B cell-containing controls ( fig. S11E ), the peritoneal cavity of GM/μMT chimeras had more leukocytes, mostly neutrophils (Fig. 4C) , and experienced a severe IL-1β, IL-6 and TNFα cytokine storm in the serum (Fig. 4D ) and peritoneum (Fig. 4E ). This inflammatory signature typically associates with a defect in bacterial clearance. Indeed, neutrophils from the GM/μMT chimeras phagocytosed bacteria poorly (Fig. 4F ). The GM/μMT chimeras, moreover, had a modest reduction of serum IgM but not IgG (Fig. 4G) , and developed severe liver and lung pathologies (Fig. 4H ). Finally, bacterial titre measurements revealed that GM/μMT chimeras were more infected than controls (Fig. 4, I and J) . Although it is possible that other bone marrow cells contribute GM-CSF for the protection against sepsis in this setting, the most likely explanation is that IRA-B cells protect against septic shock by controlling the organism's ability to clear bacteria.
GM-CSF is a pleiotropic cytokine that influences the production, maturation, function, and survival of its target cells. GM-CSF's role in sepsis has remained elusive because its indiscriminate ablation is protective (27) but its supplementation can be beneficial (28) . The in vivo identification of GM-CSF-producing B cells illustrates a previously unrecognized locational specificity that dictates the cytokine's function. IRA-B cells differ from other subsets because their pathogen recognition pathways and tissue distribution license GM-CSF expression. The function is important in sepsis and gives rise to questions as to how IRA-B cells participate in other infectious and inflammatory diseases.
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